Trials / Completed
CompletedNCT05129202
Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases
Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases：A Retrospective Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- Hunan Province Tumor Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Non-small cell lung cancer patients may have brain metastases at diagnosis. Patients with brain metastasis may contribute as poor prognosis factors. This trial aims to explore the efficacy and the safety of immune checkpoint inhibitors in non small cell lung cancer patients with initial brain metastasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | immune therapy | The patient receives immunotherapy |
Timeline
- Start date
- 2017-11-03
- Primary completion
- 2021-09-05
- Completion
- 2022-10-01
- First posted
- 2021-11-22
- Last updated
- 2023-04-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05129202. Inclusion in this directory is not an endorsement.